ZA971887B - Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof - Google Patents

Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof

Info

Publication number
ZA971887B
ZA971887B ZA971887A ZA971887A ZA971887B ZA 971887 B ZA971887 B ZA 971887B ZA 971887 A ZA971887 A ZA 971887A ZA 971887 A ZA971887 A ZA 971887A ZA 971887 B ZA971887 B ZA 971887B
Authority
ZA
South Africa
Prior art keywords
pyrimido
pyrimidines
processes
preparation
pharmaceuticals containing
Prior art date
Application number
ZA971887A
Other languages
English (en)
Inventor
Frank Himmelsbach
Georg Dahmann
Thomas Von Rueden
Thomas Metz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of ZA971887B publication Critical patent/ZA971887B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA971887A 1996-03-06 1997-03-05 Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof ZA971887B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19608588A DE19608588A1 (de) 1996-03-06 1996-03-06 Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ZA971887B true ZA971887B (en) 1998-09-07

Family

ID=7787345

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA971887A ZA971887B (en) 1996-03-06 1997-03-05 Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof

Country Status (30)

Country Link
US (1) US5821240A (xx)
EP (1) EP0888351B1 (xx)
JP (1) JP2000506151A (xx)
KR (1) KR19990087504A (xx)
CN (1) CN1064362C (xx)
AR (1) AR006108A1 (xx)
AT (1) ATE252101T1 (xx)
AU (1) AU730376B2 (xx)
BG (1) BG63163B1 (xx)
BR (1) BR9707839A (xx)
CA (1) CA2248720A1 (xx)
CO (1) CO4650043A1 (xx)
CZ (1) CZ281598A3 (xx)
DE (2) DE19608588A1 (xx)
EE (1) EE9800278A (xx)
HK (1) HK1018450A1 (xx)
HU (1) HUP9902049A3 (xx)
IL (1) IL125342A0 (xx)
MX (1) MX9807073A (xx)
NO (1) NO311522B1 (xx)
NZ (1) NZ331545A (xx)
PL (1) PL328719A1 (xx)
RU (1) RU2195461C2 (xx)
SK (1) SK120898A3 (xx)
TR (1) TR199801755T2 (xx)
TW (1) TW454008B (xx)
UA (1) UA54421C2 (xx)
UY (1) UY24474A1 (xx)
WO (1) WO1997032880A1 (xx)
ZA (1) ZA971887B (xx)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
DE10115921A1 (de) 2001-03-30 2002-10-02 Boehringer Ingelheim Pharma Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
EP1300146A1 (en) * 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
US20040242888A1 (en) * 2001-12-27 2004-12-02 Takae Ono Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP4936897B2 (ja) * 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
KR101139038B1 (ko) 2005-06-28 2012-05-02 삼성전자주식회사 피리미도피리미딘 유도체 및 이를 이용한 유기 박막 트랜지스터
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
ES2435454T3 (es) * 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
JP2009215259A (ja) * 2008-03-12 2009-09-24 Ube Ind Ltd ３−ハロゲノ−４−ヒドロカルビルオキシニトロベンゼン化合物の製造方法
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
EP2398797B1 (en) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
US20130084287A1 (en) 2011-09-30 2013-04-04 Genentech, Inc. Diagnostic markers
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
RU2739942C2 (ru) 2014-12-24 2020-12-30 Дженентек, Инк. Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
EP3807276A2 (en) 2018-06-12 2021-04-21 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
JOP20210154B1 (ar) 2018-12-20 2023-09-17 Amgen Inc مثبطات kif18a
JP2022513971A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
AU2020280024A1 (en) 2019-05-21 2021-12-09 Amgen Inc. Solid state forms
JP2022542392A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
EP4007752A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
EP4054720A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
EP4055028A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
JP2023512175A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
EP4100409A1 (en) 2020-02-03 2022-12-14 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3049207A1 (de) * 1980-12-27 1982-07-29 Dr. Karl Thomae Gmbh, 7950 Biberach Neue trisubstituierte pyrimido (5,4-d) pyrimidine, ihre herstellung und ihre verwendung als arzneimittel
DE4431867A1 (de) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
AU730376B2 (en) 2001-03-08
BG102789A (en) 1999-09-30
NO311522B1 (no) 2001-12-03
WO1997032880A1 (de) 1997-09-12
EP0888351A1 (de) 1999-01-07
EP0888351B1 (de) 2003-10-15
NO984082L (no) 1998-09-04
CO4650043A1 (es) 1998-09-03
NO984082D0 (no) 1998-09-04
CN1212694A (zh) 1999-03-31
AR006108A1 (es) 1999-08-11
DE59710864D1 (de) 2003-11-20
CZ281598A3 (cs) 1999-02-17
HK1018450A1 (en) 1999-12-24
UY24474A1 (es) 2000-09-29
TW454008B (en) 2001-09-11
UA54421C2 (uk) 2003-03-17
RU2195461C2 (ru) 2002-12-27
SK120898A3 (en) 1999-02-11
BG63163B1 (bg) 2001-05-31
CA2248720A1 (en) 1997-09-12
IL125342A0 (en) 1999-03-12
CN1064362C (zh) 2001-04-11
KR19990087504A (ko) 1999-12-27
MX9807073A (es) 1998-12-31
PL328719A1 (en) 1999-02-15
AU2094597A (en) 1997-09-22
JP2000506151A (ja) 2000-05-23
ATE252101T1 (de) 2003-11-15
NZ331545A (en) 2000-03-27
BR9707839A (pt) 1999-07-27
TR199801755T2 (xx) 1998-12-21
US5821240A (en) 1998-10-13
HUP9902049A2 (hu) 1999-10-28
HUP9902049A3 (en) 2000-03-28
EE9800278A (et) 1999-02-15
DE19608588A1 (de) 1997-09-11

Similar Documents

Publication Publication Date Title
ZA971887B (en) Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof
ZA971886B (en) Pyrimido[5,4-d]pyrimidines pharmaceuticals containing them their use and processes for the preparation thereof
HUP9801336A3 (en) 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and pharmaceutical compositions containing them
HK1001618A1 (en) Novel pyrimidine derivatives and processes for the preparation thereof
HUP9900330A3 (en) Pyrrolopyrimidines and processes for the preparation thereof
HUP0103472A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
HUP0002104A3 (en) Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0100202A3 (en) Novel triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
AP9400654A0 (en) Novel imidazole compounds, processes for the preparation thereof and their use in therapay
HK1026418A1 (en) Novel pyrimidine derivatives and processes for the preparation thereof
HU9801587D0 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives
HUP9802552A3 (en) Piperazino derivatives process for their preparation, pharmaceuticals containing the same and their use
HUP0002839A3 (en) Pyrrolo[3,4-d]pyrimidinone derivatives, their use, pharmaceutical compositions containing them, process for their preparation
NZ322197A (en) Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
HUP9801394A3 (en) 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
HU9502726D0 (en) [1,2,4]triazolo[4,3-a]qunoxaline derivatives, their preparation and use
IL110509A0 (en) Pyrimido pyrimidine compounds, their preparation and pharmaceutical compositions containing them
IL131645A (en) Pyrimido ¬1,2-a¾indole derivatives and their preparation
IL109437A0 (en) 2-Amino-4-quinolyldihydropyridines, processes for their preparation and their use
AU2141695A (en) Imidazo{1,2-a}pyrazine-4-one derivatives, preparation thereof and drugs containing same
HU9403021D0 (en) 7-disubstituted-methyl-4-oxo-3h,5h-pyrrolo[3,2-d]pyrimidine and pharmaceutical compositions containing them
IL150163A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND SOME NOVEL SUCH COMPOUNDS
ZA957464B (en) Pyrimido[5,4-d]pyrimidines medicaments comprising these compounds their use and processes for the preparation
IL108664A0 (en) Pyrimidine derivatives, their preparation and their use as pesticides
HUP0104533A3 (en) Novel pyrimidine derivatives and processes for the preparation thereof and medicaments containing them